The FDA Remestemcel-L submission for 2024 marks a significant moment in the world of biotechnology. As we await the outcomes of the review process, the potential for this therapy to transform the treatment landscape for steroid-refractory acute graft-versus-host disease is both exciting and promising.For patients, families, and healthcare providers, Remestemcel-L represents a beacon of hope, offering a new avenue for addressing a challenging condition. For the biotech industry, it highlights the ongoing advancements and the potential of innovative therapies to make a meaningful impact.
Thanks LED.
Aloha.
Cell Therapy News/Articles, page-17919
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
-0.010(1.03%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 95.0¢ | $2.617M | 2.715M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 107932 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 34142 | 1 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |